{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:07:51Z","timestamp":1774534071263,"version":"3.50.1"},"reference-count":39,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1136\/dtb.2025.000051","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:20:14Z","timestamp":1772648414000},"page":"52-57","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["\u25bcZuranolone for the treatment of moderate or severe postnatal depression"],"prefix":"10.1136","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct04442503","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02978326","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04442503","registry":"10.18810\/clinical-trials-gov"}],"member":"239","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2026032606151056000_64.4.52.1","unstructured":"Biogen . European Union (EU) Risk Management Plan (RMP) for Zurzuvae (Zuranolone). 2025. Available: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-receives-european-commission-approval-zurzuvaer"},{"key":"2026032606151056000_64.4.52.2","article-title":"Brexanolone, zuranolone and related neurosteroid GABAA receptor positive allosteric modulators for postnatal depression","volume":"6","author":"Wilson","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032606151056000_64.4.52.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022152","article-title":"Depression, depressive symptoms and treatments in women who have recently given birth: UK cohort study","volume":"8","author":"Petersen","year":"2018","journal-title":"BMJ Open"},{"key":"2026032606151056000_64.4.52.4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00737-011-0228-0","article-title":"Postpartum depression: the distribution of severity in a community sample","volume":"14","author":"Pollack","year":"2011","journal-title":"Arch Womens Ment Health"},{"key":"2026032606151056000_64.4.52.5","doi-asserted-by":"crossref","first-page":"950004","DOI":"10.3389\/fphar.2022.950004","article-title":"Comparative efficacy and acceptability of pharmacotherapies for postpartum depression: A systematic review and network meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026032606151056000_64.4.52.6","unstructured":"National Institute for Health and Care Excellence . Depression - antenatal and postnatal: what are the risk factors. 2025. Available: https:\/\/cks.nice.org.uk\/topics\/depression-antenatal-postnatal\/background-information\/risk-factors\/ [Accessed 11 Dec 2025]."},{"key":"2026032606151056000_64.4.52.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.11.007"},{"key":"2026032606151056000_64.4.52.8","doi-asserted-by":"crossref","unstructured":"Cosgrove L , Kostic M , Mintzes B , et al . Zuranolone: A case study in (regulatory) rush to judgement? Br J Clin Pharmacol 2026;4. doi:10.1002\/bcp.70472","DOI":"10.1002\/bcp.70472"},{"key":"2026032606151056000_64.4.52.9","unstructured":"National Institute for Health and Care Excellence . Zuranolone for treating postnatal depression [ID6431]: Draft guidance. 2025. Available: https:\/\/www.nice.org.uk\/guidance\/gid-ta11356\/documents\/draft-guidance [Accessed 26 Oct 2025]."},{"key":"2026032606151056000_64.4.52.10","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression","volume":"32","author":"Kanes","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"2026032606151056000_64.4.52.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31264-3"},{"key":"2026032606151056000_64.4.52.12","unstructured":"Food and Drug Administration . Sage therapeutics, inc.; withdrawal of approval of a new drug application for zulresso (brexanolone) solution, 100 milligrams\/20 milliliters. 2025. Available: https:\/\/www.federalregister.gov\/documents\/2025\/03\/14\/2025-04101\/sage-therapeutics-inc-withdrawal-of-approval-of-a-new-drug-application-for-zulresso-brexanolone [Accessed 26 Oct 2025]."},{"key":"2026032606151056000_64.4.52.13","unstructured":"Biogen Netherlands B.V . Zurzuvae 25 mg hard capsules. summary of product characteristics. 2025. Available: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/e0c8ec08eee419514af2518c74c75bf801ec3d1b [Accessed 26 Oct 2025]."},{"key":"2026032606151056000_64.4.52.14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.58347\/tml.2023.1692a","article-title":"Zuranolone (Zurzuvae) \u2013 An Oral Drug for Postpartum Depression","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"key":"2026032606151056000_64.4.52.15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2026032606151056000_64.4.52.16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220785"},{"key":"2026032606151056000_64.4.52.17","unstructured":"Medicines and healthcare products regulatory agency. public assessment report: national procedure: zurzuvae 20 mg hard capsules, zurzuvae 25 mg hard capsules, zurzuvae 30 mg hard capsules, zuranolone. 2025."},{"key":"2026032606151056000_64.4.52.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"2026032606151056000_64.4.52.19","unstructured":"Biogen . A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD). 2020. Available: https:\/\/clinicaltrials.gov\/study\/NCT04442503"},{"key":"2026032606151056000_64.4.52.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102873","article-title":"Sensitivity to change and minimal clinically important difference of Edinburgh postnatal depression scale","volume":"66","author":"Mao","year":"2021","journal-title":"Asian J Psychiatr"},{"key":"2026032606151056000_64.4.52.21","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17103350","article-title":"Comparison of Maternal Functioning between Iranian Mothers with and without Depressive Symptoms: A Case-Control Study","volume":"17","author":"Karami Chamgurdani","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2026032606151056000_64.4.52.22","doi-asserted-by":"publisher","DOI":"10.3310\/hta14080"},{"key":"2026032606151056000_64.4.52.23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/psymed.2022.0002","article-title":"A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression","volume":"1","author":"Nayak","year":"2023","journal-title":"Psychedelic Medicine"},{"key":"2026032606151056000_64.4.52.24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/jwh.2020.8483","article-title":"Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making","volume":"30","author":"Gerbasi","year":"2021","journal-title":"J Womens Health (Larchmt)"},{"key":"2026032606151056000_64.4.52.25","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-5-36","article-title":"Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial","volume":"5","author":"Hermens","year":"2007","journal-title":"BMC Med"},{"key":"2026032606151056000_64.4.52.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.120541","article-title":"The ability of EQ-5D-5L and WHODAS 2.0 to detect relevant change in primary health care outpatients with diagnosed depression","volume":"394","author":"\u00c4mm\u00e4l\u00e4","year":"2026","journal-title":"J Affect Disord"},{"key":"2026032606151056000_64.4.52.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11600","article-title":"Use of Patient-Reported Outcome Measures to Assess Outpatient Postpartum Recovery: A Systematic Review","volume":"4","author":"Sultan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026032606151056000_64.4.52.28","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13260"},{"key":"2026032606151056000_64.4.52.29","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2334160"},{"key":"2026032606151056000_64.4.52.30","unstructured":"National Institute for Health and Care Excellence . Zuranolone for treating postnatal depression [ID6431] Technology appraisal committee B Public Committee slides, 2025. Available: https:\/\/www.nice.org.uk\/guidance\/gid-ta11356\/documents\/1 [Accessed 11 Dec 2025]."},{"key":"2026032606151056000_64.4.52.31","unstructured":"U.S. Food and Drug Administration . FDA approves first oral treatment for postpartum depression. 2023. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-treatment-postpartum-depression [Accessed 29 Oct 2025]."},{"key":"2026032606151056000_64.4.52.32","unstructured":"European Medicines Agency . Zurzuvae: zuranolone. EMADOC-628903358-125643 Committee for Medicinal Products for Human Use (CHMP) Summary of opinion (initial authorisation). 2025. Available: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-zurzuvae_en.pdf"},{"key":"2026032606151056000_64.4.52.33","unstructured":"National Institute for Health and Care Excellence . Postnatal care nice guideline. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng194\/resources\/postnatal-care-pdf-66142082148037 [Accessed 11 Dec 2025]."},{"key":"2026032606151056000_64.4.52.34","unstructured":"U.S. Food and Drug Administration . Multi-discipline review: NDA 217369 (Zurzuvae\/zuranolone). Center for Drug Evaluation and Research; 2023. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217369Orig2s000IntegratedR.pdf [Accessed 20 Feb 2026]."},{"key":"2026032606151056000_64.4.52.35","unstructured":"National Institute for Health and Care Excellence . Zuranolone for treating postnatal depression [ID6431]: In development; Reference number:GID-TA11356. 2025. Available: https:\/\/www.nice.org.uk\/guidance\/GID-TA11356\/documents\/draft-guidance [Accessed 21 Feb 2026]."},{"key":"2026032606151056000_64.4.52.36","unstructured":"Scottish Medicines Consortium.Medicines Advice . Zuranolone (SMC2862). 2026. Available: https:\/\/scottishmedicines.org.uk\/media\/9786\/zuranolone-zurzuvae-final-jan-2026-for-website.pdf"},{"key":"2026032606151056000_64.4.52.37","unstructured":"MHRA . International recognition procedure. Available: https:\/\/www.gov.uk\/government\/publications\/international-recognition-procedure [Accessed 17 Feb 2026]."},{"key":"2026032606151056000_64.4.52.38","unstructured":"Biogen Netherlands B.V . Zurzuvae 20 mg hard capsules. summary of product characteristics. 2025. Available: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/86630f4972b9b895272b4e06e020dd4d666b695f"},{"key":"2026032606151056000_64.4.52.39","unstructured":"Biogen Netherlands B.V . Zurzuvae 30 mg hard capsules. summary of product characteristics. 2025. Available: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/0e16703cd658bd9aba462b3d648fd7f82a43160b"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2025.000051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:15:25Z","timestamp":1774530925000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2025.000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,26]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/dtb.2025.000051"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2025.000051","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}